OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011
NANTES, France, Jan. 25, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced it received a milestone payment of €1.3 million from Bpifrance related to the Company’s collaborative program, EFFIMab, focused on evaluating interleukin-7 receptor antagonist OSE-127/S95011, partnered with Servier1.
This new milestone payment of €1.3 million was triggered by achieving several key steps in the development of OSE-127/S95011 including reinforcement of preclinical and translational data in ulcerative colitis (UC), completion of the Phase 1 clinical trial, obtaining the Phase 2 regulatory authorization as well as specific manufacturing steps.
Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, commented: “This new milestone payment reflects the significant progress made with OSE-127/S95011, which is now in Phase 2 under OSE’s sponsorship in ulcerative colitis, a disabling chronic inflammatory bowel disease affecting 3.3 million people in the U.S., Europe and Japan. With 70-75% of ulcerative colitis patients2 either not responding or losing response to current treatments, ulcerative colitis represents a substantial medical need. There is a large potential market in ulcerative colitis for OSE-127/S95011 as it is the only full-antagonist of IL-7R, with a novel and differentiated mechanism of action. We look forward to confirming the product’s efficacy in both ulcerative colitis and Sjögren’s syndrome, another debilitating autoimmune disease, with a trial launching soon and conducted by our partner Servier.”
OSE-127/S95011 Phase 2 in ulcerative colitis
Ulcerative colitis background
1 Servier is a global independent pharmaceutical group, governed by a non-profit foundation, with headquarters based in France.
ABOUT THE EFFIMab PROGRAM
ABOUT OSE Immunotherapeutics
Auto-immunity and inflammation platform
On Premise Strategies: CBRS and Private LTE
Creating Next-Gen Collaborative Post-Pandemic Work Environments